136 related articles for article (PubMed ID: 30141571)
1. Hepatitis C virus infection in patients with end-stage renal disease.
Wigneswaran J; Van Wyck D; Pegues D; Gholam P; Nissenson AR
Hemodial Int; 2018 Jul; 22(3):297-307. PubMed ID: 30141571
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
Alsaran K; Sabry A; Molhem A
Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatitis C virus infection in patients with end-stage renal disease.
Liu CH; Kao JH
J Gastroenterol Hepatol; 2011 Feb; 26(2):228-39. PubMed ID: 21261711
[TBL] [Abstract][Full Text] [Related]
4. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus infection in end-stage renal disease and kidney transplantation.
Burra P; Rodríguez-Castro KI; Marchini F; Bonfante L; Furian L; Ferrarese A; Zanetto A; Germani G; Russo FP; Senzolo M
Transpl Int; 2014 Sep; 27(9):877-91. PubMed ID: 24853721
[TBL] [Abstract][Full Text] [Related]
6. When and how can nephrologists treat hepatitis C virus infection in dialysis patients?
Davis MI; Chute DF; Chung RT; Sise ME
Semin Dial; 2018 Jan; 31(1):26-36. PubMed ID: 28925068
[TBL] [Abstract][Full Text] [Related]
7. Management of hepatitis C infection among patients with renal failure.
Latt NL; Araz F; Alachkar N; Durand CM; Gurakar A
Minerva Gastroenterol Dietol; 2015 Mar; 61(1):39-49. PubMed ID: 25390288
[TBL] [Abstract][Full Text] [Related]
8. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
9. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment.
Selcuk H; Kanbay M; Korkmaz M; Gur G; Akcay A; Arslan H; Ozdemir N; Yilmaz U; Boyacioglu S
Dig Dis Sci; 2006 Aug; 51(8):1420-5. PubMed ID: 16868830
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Toyoda H; Kumada T; Tada T; Takaguchi K; Ishikawa T; Tsuji K; Zeniya M; Iio E; Tanaka Y
J Gastroenterol; 2016 Jul; 51(7):741-7. PubMed ID: 26872889
[TBL] [Abstract][Full Text] [Related]
11. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
[TBL] [Abstract][Full Text] [Related]
12. Clinical and laboratory characteristics of acute hepatitis C in patients with end-stage renal disease on hemodialysis.
Lemos LB; Perez RM; Matos CA; Silva IS; Silva AE; Ferraz ML
J Clin Gastroenterol; 2008 Feb; 42(2):208-11. PubMed ID: 18209594
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Surendra M; Raju SB; Sridhar N; Vijay Kiran B; Rajesh G; Anvesh G; Raju N
Hemodial Int; 2018 Apr; 22(2):217-221. PubMed ID: 28972699
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus in chronic dialysis patients.
Natov SN; Pereira BJ
Minerva Urol Nefrol; 2005 Sep; 57(3):175-97. PubMed ID: 15986016
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of viral hepatitis in solid organ transplantation].
Mikolašević I; Sladoje-Martinović B; Orlić L; Milić S; Lukenda V; Župan Ž; Štimac D; Rački S
Acta Med Croatica; 2014 Apr; 68(2):151-9. PubMed ID: 26012153
[TBL] [Abstract][Full Text] [Related]
16. [Viral hepatitis C in patients with terminal chronic renal insufficiency. III. Viral quantification].
González-Michaca L; Soto-Ramírez LE; Rodríguez R; Gamba G
Rev Invest Clin; 2001; 53(1):21-7. PubMed ID: 11332047
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
[TBL] [Abstract][Full Text] [Related]
18. HCV and the kidney.
Corouge M; Vallet-Pichard A; Pol S
Liver Int; 2016 Jan; 36 Suppl 1():28-33. PubMed ID: 26725894
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant.
Kamar N; Ribes D; Izopet J; Rostaing L
Transplantation; 2006 Oct; 82(7):853-6. PubMed ID: 17038897
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of hepatitis B and hepatitis C virus infections by serological and molecular methods in hemodialysis patients].
Dağlar D; Ergani A; Demirbakan H; Ozhak Baysan B; Ongüt G; Koçak H; Oğünç D; Akbaş H; Yıldırım B; Colak D
Mikrobiyol Bul; 2014 Jan; 48(1):143-50. PubMed ID: 24506725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
